期刊文献+

糖肾化浊方治疗Ⅳ期糖尿病肾病的疗效分析 被引量:1

Effects of tang shen hua zhuo recipe in patients with Ⅳ stage of Diabetic Nephropathy
下载PDF
导出
摘要 目的观察糖肾化浊方治疗Ⅳ期糖尿病肾病的临床疗效。方法 100例Ⅳ期糖尿病肾病患者随机分为治疗组和对照组,各50例。治疗组口服糖肾化浊方免煎颗粒,每日2次,并联合厄贝沙坦150mg/d;对照组口服厄贝沙坦150mg/d。观察尿微量白蛋白排泄率,同时测定空腹血糖、糖化血红蛋白、血肌酐、尿素氮、血脂等。结果按方案完成98例,治疗组48例,对照组50例。6个月后,治疗组尿微量白蛋白排泄率、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇均优于对照组(P<0.01)。结论糖肾化浊方能有效改善Ⅳ期糖尿病肾病。 Objective To observe the effects of Tang shen hua zhuo Recipe (TSHZR) in the treatment of patients from IV stage of diabetic nephropathy. Method One hundred patients with Ⅳ stage DN were randomly assigned into the control group (n=50)treated by irbesartan alone and the treated group (n= 50)treated by TSHZR combined with irbesartan for 6 months. All patients received diabetes fundamental drug. The urine albumin excretion rate was used as the assessment index of therapeutic effect, and fasting blood glucose, HbA1 c, serum creatinine, blood urea ni- trogen and lipid profiles ,were examined as well. Result According to the protocol complete observation of 98 cases, 48 cases in treatment group and control group of 50 cases. The clinical control rates were significantly differences observed among the two groups. After treatment the urine albumin excretion rate, the levels of triglyceride, total cho- lesterol and low density lipid cholesterol in treatment group all significantly lower than control group ( P〈0.01 ), and the levels high density lipid cholesterol in treatment group significantly higher than control group ( P〈0.01 ). Conclusion The results show that TSHZR can effectively improve Ⅳ stage of diabetic nephropathy, compared with irbesartan has more advantages.
出处 《中国临床医生杂志》 2014年第5期43-45,共3页 Chinese Journal For Clinicians
关键词 糖肾化浊方 糖尿病肾病 尿微量白蛋白排泄率 Tang Shen Hua Zhuo Recipe Diabetic Nepbropathy Urine Albumin Excretion Rate
  • 相关文献

参考文献11

二级参考文献27

  • 1赵怡蕊,刘光珍,宋跃飞,韩履祺.芪术汤治疗糖尿病肾病的疗效观察[J].中国中西医结合肾病杂志,2006,7(4):230-231. 被引量:18
  • 2Gu Y,Lai LY.Advance of renin-angiotensin systems in the research of diabetic nephropathy[J]. Chinese Journal of Nephrology,2004,20(3):221.
  • 3Brezniceanu RE,Zniceanu NI,Ceanu ML,et al.Transforming growth factor-beta 1 stimulates angiotensinogen gene expression in kidney proximal tubular cells[J]. Kidney International,2006,69(11):1977-1985.
  • 4Wang HY,Hu DY.The effect of Clinical Efficacy of angiotensinⅡreceptor blockers[J]. Chinese Journal of Medicine,2005,40(11):62.
  • 5Zweiker R,Stosch itzky K,M aier R.Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension[J]. Acta Medica Austriaca,2002,29(2):72-76.
  • 6Junaid A,Rosenberg ME,Hostetter TH.Interaction of angiotensinⅡand TGF-beta 1 in the rat remnant kidney[J]. Am Soc Nephrol,1997,8(11):1732-1738.
  • 7Suzuki Katsunori,Souda Satosh I,Ikarash I Tom OO,et al.Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy[J]. Diabetes Researchand Clinical Practice,2003,57(2):179-183.
  • 8Ko GT,Tsang CC,Chan HC.Tabilization and regression of album-inuria in chinese patients with Type 2 diabetes:a one-year randomized study of valsartan versus enalapril[J]. Advances in Therapy,2005,22(2):155-162.
  • 9Mason RM,Wahab NA.Extracellular matrix metabolism in diabetic nephropathy.J Am Soc Nephrol,2003,14 (5):1358-1373.
  • 10van Nieuwenhoven FA,Jensen L J,Flyvbjerg A,et al.Imbalance of growth factor signalling in diabetic kidney disease:is connective tissue growth factor (CTGF,CCN2) the perfect intervention point?Nephrol Dial Transplant,2005,20(1):6-10.

共引文献210

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部